Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 CAEL-101 plus plasma cell dyscrasia treatment vs placebo in Mayo stage IIIa AL amyloidosis
2020-000713-32Phase 3Active
- Sponsor
- Caelum Biosciences
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis and amyloid cardiomyopathy comparing CAEL-101 arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started Sep 2020; status: active.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosisamyloid cardiomyopathy
Beyond the preview
Go deeper on 2020-000713-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000713-32.